I. Approval Criteria
A. Erleada
When a benefit, coverage of Erleada may be approved when all of the following criteria are met (1. and 2.):
1. The member meets one (1) of the following criteria (a. or b.):
a. The member has a diagnosis of non-metastatic castration-resistant prostate cancer.
b. The member has a diagnosis of metastatic castration-sensitive prostate cancer.
2. The member meets one of the following criteria (a. or b.):
a. Erleada is being used in combination with a GnRH analog.
b. The member has had a bilateral orchiectomy.
B. Nubeqa
When a benefit, coverage of Nubeqa may be approved when all of the following criteria are met (1. and 2.):
1. The member has a diagnosis of non-metastatic castration-resistant prostate cancer.
2. The member meets one of the following criteria (a. or b.):
a. Nubeqa is being used in combination with a GnRH analog.
b. The member has had a bilateral orchiectomy.
C. Xtandi
When a benefit, coverage of Xtandi may be approved when the following criterion is met (1.):
1. The member has a diagnosis of castration-resistant prostate cancer.
II. For Medicare Part D beneficiaries, an androgen receptor inhibitor may be approved when used for a medically accepted indication as defined by the Centers for Medicare & Medicaid Services (CMS).